Physician profile
Amy E Forsee
NPI 1457459315
$3,610.93
in general payments reported to CMS, 2019-2025
34 companies · $911 in 2025
The $911 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $398 · 2021: $99.29 · 2022: $400 · 2023: $564 · 2024: $743 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.09 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $437.42 | 2020-2025 | |
| Novo Nordisk INC | $430.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $393.27 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $372.03 | 2019-2025 | |
| Glaxosmithkline, LLC. | $343.55 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $231.29 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.77 | 2019-2025 | Jardiance, Ofev |
| Abbott Laboratories | $173.98 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.39 | 2020-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $125.17 | 2019-2025 | |
| Allergan, INC. | $93.08 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $90.46 | 2019-2023 | Camzyos |
| Amgen INC. | $85.52 | 2020-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $51.59 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.92 | 2025 | Caplyta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $45.15 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $29.48 | 2019-2022 | |
| Madrigal Pharmaceuticals | $28.24 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $27.33 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.10 | 2023-2024 | |
| Astellas Pharma US INC | $21.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.12 | 2019 | |
| Philips North America LLC | $18.98 | 2023 | |
| Ibsa Pharma INC. | $18.17 | 2025 | Licart, Tirosint, Flector |
| Ars Pharmaceuticals Operations, INC. | $18.11 | 2025 | Neffy |
| Axsome Therapeutics, INC. | $16.39 | 2025 | Auvelity |
| Sanofi Pasteur INC. | $15.19 | 2019 | |
| Exact Sciences Corporation | $14.74 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $14.45 | 2019 | |
| Hikma Pharmaceuticals USA | $14.44 | 2019 | |
| Valeritas, INC. | $13.64 | 2019 | |
| Eisai INC. | $13.14 | 2020 | |
| Antares Pharma, INC. | $12.86 | 2022 | |
| Assertio Therapeutics, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Forsee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.